RYGB new.png

About


Treating Obesity

By pharmacological mimicry of

gastric bypass microbiome

Learn More

SCROLL DOWN

About


Treating Obesity

By pharmacological mimicry of

gastric bypass microbiome

Learn More

 

Xeno is a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.   

 
RYGB new.png

Technology


Gastric bypass surgery alters the gut microbiome and leads to weight loss

Xeno is developing a first-in-class

pharmacotherapy to mimic

the surgery-induced microbiome

shift and weight loss

Technology


Gastric bypass surgery alters the gut microbiome and leads to weight loss

Xeno is developing a first-in-class

pharmacotherapy to mimic

the surgery-induced microbiome

shift and weight loss